GH secretagogues, GHRH analogues, and IGF-1 for growth hormone axis research.
COA ✓
🔥 Popular
NEW BATCH
COA ✓
🔥 Popular
NEW BATCH
Growth hormone peptides modulate the hypothalamic-pituitary axis to stimulate endogenous GH release. This category spans GHRH analogues like CJC-1295 and Sermorelin, ghrelin mimetics such as Ipamorelin and GHRP-6, and direct growth factors including HGH and IGF-1 LR3. Together, they represent the most well-characterized peptide class in endocrinology research.
| Peptide | Class | Mechanism | Dosage | Profile |
|---|---|---|---|---|
| HGH | Direct GH | 191-amino acid somatotropin | 10 IU | Exogenous growth hormone |
| CJC-1295 DAC | GHRH | Sustained GHRH receptor activation | 5mg | Long half-life (8-10 days) |
| CJC-1295 No DAC | GHRH | Pulsatile GHRH release | 10mg | Short half-life, natural pulse |
| Ipamorelin | GHRP | GHS-R1a selective agonist | 10mg | Cleanest GH release profile |
| GHRP-2 | GHRP | Potent ghrelin mimetic | 10mg | Strongest GH pulse, hunger effect |
| Hexarelin | GHRP | GHS-R1a agonist + cardiac | 3mg | Cardioprotective properties |
| IGF-1 LR3 | Growth Factor | IGF-1 receptor, extended half-life | 1mg | Downstream GH effector |
Understanding the growth hormone axis is essential for selecting the right peptide for a given research objective. GHRH analogues and ghrelin mimetics work at different points in the signaling cascade.
CJC-1295, Sermorelin, and Tesamorelin bind to GHRH receptors on pituitary somatotrophs, directly stimulating GH synthesis and release. The DAC (Drug Affinity Complex) modification on CJC-1295 extends albumin binding and half-life.
Ipamorelin, GHRP-2, GHRP-6, and Hexarelin activate the growth hormone secretagogue receptor (GHS-R1a). When combined with a GHRH analogue, the two pathways produce a GH pulse far greater than either alone.
All GH peptides require bacteriostatic water for reconstitution. Use our reconstitution calculator and dosage calculator for precise measurements. For syringe volume conversions, see the syringe unit calculator.